Altered VEGFR3 expression and activity are also linked to diseases, such as Milroy disease, lymphedema, tumor-associated lymphangiogenesis, and lymphatic metastasis (45), where VEGFR3 is used as a drug target. This evidence concerns the gene FLT4 and lymphedema.